Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
5.34
-0.05 (-0.93%)
Dec 12, 2025, 10:58 AM EST - Market open
Compass Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Compass Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $13.44, which forecasts a 151.69% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $30.
Price Target: $13.44 (+151.69%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Compass Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 5 |
| Buy | 4 | 3 | 3 | 3 | 3 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 8 | 8 | 7 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 3, 2025 |
| Citizens | Citizens | Buy Initiates $10 | Buy | Initiates | $10 | +87.27% | Dec 3, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +87.27% | Dec 3, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +461.80% | Nov 5, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $32 | Strong Buy | Maintains | $32 | +499.25% | Aug 12, 2025 |
Financial Forecast
Revenue This Year
n/a
from 850.00K
Revenue Next Year
11.05M
EPS This Year
-0.46
from -0.36
EPS Next Year
-0.50
from -0.46
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 41.3M | ||||
| Avg | n/a | 11.0M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.39 | -0.22 | ||||
| Avg | -0.46 | -0.50 | ||||
| Low | -0.58 | -0.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.